Background: To evaluate the efficacy and toxicity of single-agent docetaxel (Taxotere) as therapy in patients with disseminated nasopharyngeal carcinoma (NPC). Results: Thirty patients were assessable for toxicity and response. The median age of the patients was 47 years (range 25-68 years) and the majority of patients had good performance status (Eastern Cooperative Oncology Group 0-1). Grade 3 or 4 toxicity included fatigue (13%), anemia (10%) and diarrhea (3%) of patients. Eleven (37%) and four (13.3%) patients achieved partial response and stable disease, respectively. The median progression-free survival was 5.3 months and median overall survival of 12.8 months. The partial responders had a mean duration of response of 4.1 months. Docetaxel caused a significant decline in QoL scores during treatment of patients responding or progressing with the treatment.
introduction
It is a well-established fact that nasopharyngeal carcinoma (NPC) is a chemoresponsive disease and despite improvement in outcome of patients with locally advanced stage III/IV disease with the addition of platinum-based chemotherapy as combined modality therapy with radiation, systemic failure continues to be a problem [1, 2] . Over the past decade, our group has established the activity of several third-generation cytotoxics in NPC, including paclitaxel, gemcitabine and irinotecan [3] [4] [5] [6] . Most of these chemotherapeutic agents are cell cycle phase specific and combinational therapy with drugs that can enhance their cytotoxic effects will be critical in further improving their therapeutic efficiency.
Weekly docetaxel is a well-studied regimen in several solid tumors, such as breast or lung cancer [7] [8] [9] [10] . Although the weekly docetaxel regimen was shown to have similar efficacy compared with the three weekly regimen, it had a more favorable toxicity profile. The objective of this study was to investigate the efficacy of weekly docetaxel in patients with metastatic NPC who had failed at least one line of palliative chemotherapy.
patients and methods eligibility criteria and pretreatment evaluation
The main inclusion criteria include histologically confirmed diagnosis of NPC, an Eastern Cooperative Oncology Group performance status of zero to two, and no prior use of docetaxel (Taxotere) (Sanofi Aventis, France) [prior paclitaxel use was allowed], adequate hematologic renal and liver function using standard laboratory measurements and the absence of brain/ leptomeningeal metastases. Written informed consent was obtained from all patients who met the eligibility criteria before enrollment in this study. The study was approved by the Health Sciences Authority (Singapore) and the institutional review board. /l or platelet <100 000/ll. Subsequent cycle was delayed in patients who experienced any grade 3 or 4 nonhematologic toxicity and resumed when the toxicity improved to grade £ 2. Weekly evaluations were carried out in patients who had dose delays and beyond a maximal delay period of 21 days, the patient's participation in the study was discontinued.
treatment regimen and dose modification

pretreatment, response and toxicity evaluation
Computed tomography scans or magnetic resonance images of all evaluable and measurable disease sites were obtained within 21 days of study treatment as baseline and after every two cycles until cycle 6 and every 2 months thereafter until disease progression was documented. All responses were confirmed by subsequent scans carried out at least 4 weeks post-initial response. Response and toxicity were evaluated with the RECIST criteria and National Cancer Institute-Common Toxicity Criteria version 3, respectively. A maximum of six cycles was allowed for responding or stable patients.
quality-of-life assessment
The quality of life (QoL) of patients during treatment was assessed using the European Organization for Research and Treatment of Cancer QoL questionnaire (QLQ-C30; version 3.0) at study entry and before every cycle of docetaxel. The global health status was analyzed to investigate the overall level of patient QoL. Impact of docetaxel on functional scales and symptom scales of QLQ-C30 was also examined. The scores were transformed to a 0-100 scale and the 'half-rule' was used to impute missing values. A higher score denoted better QoL.
statistical analysis
Using a Simon 2-stage minimax design, a lower activity level (p0) of 0.05 and a target activity level (p1) of 0.20, the planned accrual of 30 patients was sufficient to test this hypothesis (type 1 error, 0.05 and type II error, 0.20) [11] . These parameters were based on the results of two prospective trials of irinotecan and gemcitabine that showed activity of 14% and 48%, respectively, in patients who had prior palliative chemotherapy [4, 5] . At the end of the first stage, at least one response had to be found in 13 patients before continued accrual, and efficacy would be claimed if greater than equal to four responses were observed from the total of 30 patients. The 95% confidence interval (CI) for the overall response rate was calculated using the formula described by Newcombe and Altman [12] .
The analysis was done on an intention-to-treat basis. The association between the response to prior paclitaxel and response to docetaxel was tested using Fisher's exact test. The odds ratio (OR) summarizing interval between prior paclitaxel and response to docetaxel [partial response (PR) or stable disease] was estimated by logistic regression and the 95% CIs obtained. The progression-free survival (PFS) was defined as the time of enrollment into the study to the date of documented disease progression or death from all causes, whereas overall survival (OS) was calculated from the date of enrollment into the study to date of death from any cause or to the date when the patient was last known to be alive; both were calculated with the Kaplan-Meier method. The duration of response for partial responders is defined as time of first responded to the date of documented disease progression or death. All analyses were carried out using SAS software (version 9.2; SAS, Inc., Cary, NC). QoL data were analyzed using mixed model methodology, which adjusted for bias due to missing values that depended on observed QoL scores. (Table 1) . Twenty-four patients (80%) had prior radiotherapy. A median of two lines of palliative chemotherapy (range 0-3) was administered before entry to the study: one line (12 patients), one lines (14 patients) and three lines (3 patients). One patient who was chemonaive was recruited in violation of the protocol but was included in the analysis. Seven patients had platinum-based chemoradiotherapy for primary treatment of locoregional disease. The median number of prior cytotoxic agents used was 4. All the patients had received platinum-based regimens at a median of 2 months before study entry with 63.4% of the patients treated within 3 months of study treatment.
response All 30 patients were evaluated for response. Median number of cycles of docetaxel received was 4 with 13 (43%) patients receiving all six cycles. Results of the best overall objective response are summarized in Table 2 . The best overall response response to paclitaxel did not predict for response to docetaxel (P = 1.00), and a longer interval from prior paclitaxel showed slightly higher chance of response to docetaxel (OR 1.59, 95% CI 0.86-3.00). Sites of metastatic disease did not impact on responses seen (results not shown). However, the sample size is too small for firm conclusions to be made. Nineteen patients received two or more lines of palliative chemotherapy before our study but there was no difference in responses seen (P = 1.00). Fifteen patients went on to receive salvage treatment with various regimens on progression after docetaxel treatment, most of which involved rechallenging with gemcitabine-based regimens.
survival outcome
One patient passed away without documented progressive disease (PD) and is considered as PD at death in the analysis. The median follow-up was 12.8 months. The median time to tumor progression was 5.3 months (95% CI 2.8-7.5 months) ( Figure 1 ). The median OS was 12.8 months (95% CI 5.7-24.9 months) (Figure 2 ). The partial responders had a median duration of response of 4.1 months (1.5-9.5 months).
toxicity Table 2 summarizes the hematologic and nonhematologic toxic effects. Nonhematologic toxic effects were more common and grade 3 diarrhea, fatigue and neuropathy were observed in one (3%), four (13%) and one (3%) patients, respectively. Two (7%) patients developed grade 3 hepatotoxicity. There was one death during treatment in a patient who developed pulmonary embolism and subsequent pneumonia. In general, weekly docetaxel was well tolerated with reversible nonhematologic toxicity being more common than hematologic toxicity. (17) 19 (63) original article
Annals of Oncology quality of life Figure 3 shows the impact of weekly docetaxel on the global QoL score of the patients after the second cycle of the treatment. The study population was stratified into three groups according to attrition per two cycles of treatments since patients who had worse baseline QoL may have received less cycles of treatment. Using a mixed model approach described by Fairclough [13] to adjust for the bias induced by drop out, the global QoL scores declined by 2.93 points per cycle significantly during the treatment (P < 0.001). The decline is especially seen in physical functioning and role functioning (P < 0.001).
discussion
Docetaxel is an established cytotoxic with activity against several solid tumors, including breast, lung and squamous cell head and neck cancers. Its activity in NPC has been investigated in combination with platinum in both the metastatic/recurrent and locoregionally advanced settings [14] [15] [16] [17] . Two studies used docetaxel and cisplatin, both at 75 mg/m 2 in patients with metastatic/recurrent disease. High hematological toxicity was noted in both studies with grade 3-4 neutropenia and neutropenic fever in 51%-93% and 6.8%-12.5% of the cycles, respectively [14, 15] . This necessitated a reduction of the dose of both docetaxel and cisplatin to 60 mg/m 2 in the protocol after observing 10.5% septic death rate [15] . McCarthy et al. [14] stopped recruitment at nine patients after observing only two PRs (22%) and declared the regimen inefficacious. However, Chua et al. [15] ) for two cycles [17] . This induction regimen also resulted in high response rate of 76.5% (CR 17.6%) and there was a suggestion of a positive impact on PFS and OS with neoadjuvant docetaxel and cisplatin. Although it is difficult to determine the single-agent activity of docetaxel in NPC from these studies, we can safely conclude that docetaxel is active for this disease. 28.7 months 1.9 months 53% 25.8% 
Annals of Oncology original article
To the best of our knowledge, this is the first study that confirmed the single-agent activity of docetaxel in the setting of heavily pretreated metastatic NPC. The median PFS of 5.8 months and OS of 12.8 months are encouraging, given that the majority of our patients were late in the course of progressive metastatic disease. It is noteworthy that durable responses were seen in those who achieved partial remission, which lasted a median of 4.1 months. Of interest is the observation that prior paclitaxel does not preclude the use of docetaxel in the salvage setting but this is limited by our small sample size and will require further validation.
Data relating to QoL in patients receiving chemotherapy for refractory NPC are few. This is a matter of some concern, as the American Society of Clinical Oncology has suggested that patient outcomes such as survival and QoL should be afforded higher priority than cancer outcomes (e.g. tumor response rates) in the assessment of new treatments and formulation of treatment guidelines [16] . Data are also available to indicate that QoL considerations affect patients' choices. In fact, many would not choose chemotherapy for an increase in survival of 3 months alone but would if such treatment improved QoL [17] . However, despite the increasing prominence of QoL issues in the literature, current treatment choices are still driven chiefly by survival end points, an approach that may result in suboptimal overall outcomes. The QoL evaluations showed a significant decline during treatment. Several factors may have caused the decline in patient's QoL. Firstly, although weekly docetaxel was generally well tolerated with very favorable hematological toxicity profile, fatigue is common with this schedule and could have contributed to the significant decline in physical and role functioning in QoL (Table 2) . Almost all the patients reported fatigue with this schedule with grade 2 or 3 intensity experienced in 40% of the patients. Secondly, the majority of the patients had received prior chemotherapy and represented a heavily pretreated patient population, which may have also contributed to the significant drop in QoL. It is important therefore to detect patients who are not responding to docetaxel and to stop the treatment as soon as possible, as this can contribute further to a poorer QoL in those already plagued by the ravages of progressive disease. It is possible that the QoL scores may improve above the baseline level with cessation of treatment of responders to docetaxel. Unfortunately, we did not evaluate the QoL after the completion of the last cycle of docetaxel in this study. Hence, we are unable to comment on this possibility during the post-chemotherapy recuperation period.
Incorporating docetaxel in novel combinations with other ;active agents in the first-line setting may provide the muchneeded added improvement for patients with disseminated NPC. The use of docetaxel in combination with a platinum has been shown to be active in combination with radiotherapy for locally advanced disease and the ongoing phase III study that investigates induction docetaxel/cisplatin/5-fluorouracil will determine whether docetaxel will make a difference in the primary setting [18, 19] .
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